DANVERS, Mass.--(BUSINESS WIRE)--July 17, 2006--Abiomed, Inc. (NASDAQ: ABMD - News) today announced the start of the IMPELLA® 2.5 pilot study in the United States with the enrollment of the first patient at William Beaumont Hospital in the Detroit area. The IMPELLA 2.5 is the world's smallest ventricular assist device (VAD) and is currently available in Europe under the CE Mark.
